STOCK TITAN

Inspira Technologies Oxy Bhn Ltd - IINN STOCK NEWS

Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.

Inspira Technologies Oxy BHN Ltd (IINN) delivers innovative respiratory care solutions through its non-invasive INSPIRA ART system and HYLA blood monitoring technology. This page provides investors and healthcare professionals with essential updates on regulatory milestones, product developments, and clinical partnerships shaping the future of critical care.

Access real-time information on FDA clearances, technology evaluations, and strategic collaborations. Our curated news ensures you stay informed about advancements in extracorporeal oxygenation and AI-driven blood analytics without speculative commentary.

Discover updates across key categories including regulatory submissions, clinical trial results, product launches, and global distribution agreements. All content is verified for accuracy and relevance to support informed decision-making.

Bookmark this page for streamlined access to Inspira Technologies' progress in redefining respiratory support systems. Check back regularly for authoritative reporting on innovations addressing acute respiratory failure and ICU resource challenges.

Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) has entered into a definitive agreement for the issuance and sale of 3,031,250 ordinary shares at a purchase price of $1.28 per share in a registered direct offering. The company will also issue unregistered warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (NASDAQ: IINN) Announces Breakthrough in Sensor Technology for Real-Time Blood Monitoring
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) is set to attend the 42nd Annual J.P. Morgan Healthcare Conference in January 2024. The Company's CEO and President will meet with medical device and strategic consulting companies, aiming to advance their groundbreaking life support technology. The expected FDA clearance for their innovative life support device that directly oxygenates blood is a significant milestone on the horizon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
conferences
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil, a distinguished specialist in cardiac surgery and intensive care medicine, is expected to significantly contribute to the deployment of the INSPIRA™ ART100. U.S. Food and Drug Administration (FDA) approval is expected in the first half of 2024. The company is leading the way in transforming life-support care, with innovative solutions that pave the way for direct blood oxygenation and AI-driven monitoring systems, potentially enhancing patient outcomes and streamlining hospital operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
management clinical trial
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) announces partnership with Ennocure MedTech Ltd. to develop bio-electronic technology for bloodstream infection prevention. The company aims to revolutionize life support technology by integrating oxygenation and infection prevention solutions, potentially improving patient outcomes and reducing healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) Announces Q3 Financial Results and Progress in Novel Oxygenation Technology Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
Rhea-AI Summary
Inspira Technologies has received a grant from the Israeli Innovation Authority for its VORTX Disposable Blood Oxygenation Technology. The VORTX is designed to oxygenate blood and remove carbon dioxide, addressing a $4 billion perfusion disposable market in the medical devices sector. The grant covers 40% of the first-year approved budget of $1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
Rhea-AI Summary
Inspira Technologies receives additional patent for respiratory medical device, INSPIRA ART500
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
-
Rhea-AI Summary
Inspira Technologies terminates its at-the-market equity offering program. Operations unaffected by ongoing war.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
Rhea-AI Summary
Inspira Technologies signs distribution agreement with CIO MED GROUP, potentially generating $28 million in recurring revenues
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
Inspira Technologies Oxy Bhn Ltd

Nasdaq:IINN

IINN Rankings

IINN Stock Data

15.02M
24.59M
4.01%
4.55%
0.61%
Medical Devices
Healthcare
Link
Israel
Ra'anana